Trial Profile
Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 23 Sep 2016 Status changed from recruiting to completed.
- 27 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 25 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.